0001209191-23-016099.txt : 20230303
0001209191-23-016099.hdr.sgml : 20230303
20230303210947
ACCESSION NUMBER: 0001209191-23-016099
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230301
FILED AS OF DATE: 20230303
DATE AS OF CHANGE: 20230303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Newman Mark
CENTRAL INDEX KEY: 0001524597
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36794
FILM NUMBER: 23707319
MAIL ADDRESS:
STREET 1: 1011 WARRENVILLE ROAD
STREET 2: SUITE 600
CITY: LISLE
STATE: IL
ZIP: 60532
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Chemours Co
CENTRAL INDEX KEY: 0001627223
STANDARD INDUSTRIAL CLASSIFICATION: CHEMICALS & ALLIED PRODUCTS [2800]
IRS NUMBER: 464845564
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1007 MARKET STREET
CITY: WILMINGTON
STATE: DE
ZIP: 19801
BUSINESS PHONE: 302 773 1000
MAIL ADDRESS:
STREET 1: 1007 MARKET STREET
CITY: WILMINGTON
STATE: DE
ZIP: 19801
FORMER COMPANY:
FORMER CONFORMED NAME: Chemours Company, LLC
DATE OF NAME CHANGE: 20141205
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-01
0
0001627223
Chemours Co
CC
0001524597
Newman Mark
C/O THE CHEMOURS COMPANY
1007 MARKET STREET
WILMINGTON
DE
19801
1
1
0
0
President and CEO
Common Stock
2023-03-01
4
F
0
5248
34.84
D
216118.8979
D
Common Stock
2023-03-01
4
A
0
43053
0.00
A
259171.8979
D
Common Stock
2480
I
Reporting person's children
Common Stock
32155
I
By GRAT
Stock Option (Right to Buy)
34.84
2023-03-01
4
A
0
97656
0.00
A
2033-03-01
Common Stock
97656
97656
D
Performance Stock Option (Right to Buy)
38.32
2023-03-01
4
A
0
96277
0.00
A
2033-03-01
Common Stock
96277
96277
D
Restricted Stock Unit (RSU) award scheduled to vest in three equal annual installments beginning on March 1, 2024.
Includes directly owned shares, restricted stock units and dividend equivalent units.
Shares automatically withheld to satisfy tax obligations on vesting restricted stock units. Transaction is exempt from Section 16(b) pursuant to Rule 16b-3. No shares were sold.
These options are scheduled to vest in three equal annual installments beginning on March 1, 2024.
Represents a 10 percent premium above the closing price of the Company common stock on the date of grant
/s/ Pauletta Brown, Attorney-in-Fact
2023-03-03